- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01622569
Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Extension Phase to Assess Safety
A 16-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Extension Phase to Assess Safety
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This was a randomized, double-blind, placebo-controlled, parallel-group, multicenter study designed to assess the efficacy and safety of intranasal administration of 3 doses of OPN-375 (100, 200, and 400 µg bid) in subjects with bilateral nasal polyposis and nasal congestion.
This study consisted of 3 phases. After signing informed consent, subjects who met eligibility criteria at Visit 1 (screening) entered the study.
- Pretreatment phase (single-blind, placebo, run-in): 7 to up to 14 days duration, to determine disease status eligibility and to ensure the subject was able to comply with study procedures prior to randomization and enrolment in the double-blind treatment phase.
- Double-blind treatment phase: 16 weeks duration with 6 scheduled visits starting with Visit 2, Day 1 (baseline) when eligible subjects were randomized by balance allocation to 1 of 4 treatment groups and ending at Visit 7 (Week 16).
- Open-label extension phase: 8 weeks duration with 1 scheduled visit (Visit 8 [Week 24]).
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Ontario
-
Ottawa, Ontario, Canada, K1Y 4G2
- Ottawa Allergy Research Corporation
-
-
Quebec
-
Montreal, Quebec, Canada, H2W 1T8
- CHUM Hôtel-Dieu
-
Montreal, Quebec, Canada, H3G 1L5
- Dr. Jaime Del Carpio
-
-
-
-
Arizona
-
Tucson, Arizona, United States, 85704
- SC Clinical Research, Inc.
-
-
California
-
Bakersfield, California, United States, 93301
- Kern Allergy and Medical Research, Inc.
-
Fresno, California, United States, 93720
- Central California Clinical Research
-
Huntington Beach, California, United States, 92647
- Allergy & Asthma Specialists Medical Group
-
Los Angeles, California, United States, 90025
- California Allergy & Asthma Medical Group, Inc.
-
Orange, California, United States, 92868
- Choc PSF, AMC, Division of AA & I
-
Palmdale, California, United States, 93551
- California Allergy and Asthma Palmdale
-
Rolling Hills Estates, California, United States, 90274
- Peninsula Research Associates, Inc.
-
Santa Monica, California, United States, 90404
- California Medical Clinic for Headache
-
-
Colorado
-
Colorado Springs, Colorado, United States, 80909
- Colorado ENT & Allergy
-
Colorado Springs, Colorado, United States, 80907
- Asthma & Allergy Associates, P.C.
-
Denver, Colorado, United States, 80230
- Colorado Allergy and Asthma Centers, P.C.
-
-
Florida
-
Tampa, Florida, United States, 33613
- University of South Florida Asthma, Allergy & Immunology
-
-
Illinois
-
Chicago, Illinois, United States, 60657
- Chicago ENT
-
Chicago, Illinois, United States, 60611
- NU Feinberg School of Medicine Depart. of Otolaryngology-Head & Neck Surgery
-
-
Massachusetts
-
North Dartmouth, Massachusetts, United States, 02747
- Northeast Medical Research Associates, Inc
-
-
Missouri
-
Kansas City, Missouri, United States, 64114
- The Center for Pharmaceutical Research, P.C.
-
-
Montana
-
Bozeman, Montana, United States, 59718
- Clinical Research Group of Montana, PLLC
-
-
New Jersey
-
Neptune, New Jersey, United States, 07753
- Coastal Ear, Nose and Throat, LLC
-
-
New York
-
Bronx, New York, United States, 10467
- Montefiore Medical Center
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic
-
Columbus, Ohio, United States, 43235
- Optimed Research
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73120
- Allergy, Asthma & Clinical Research Center
-
Tulsa, Oklahoma, United States, 74136
- Vital Prospects Clinical Research Institute
-
-
South Carolina
-
North Charleston, South Carolina, United States, 29420
- National Allergy, Asthma & Urticaria Centers of Charleston, P.A.
-
-
Texas
-
Dallas, Texas, United States, 75231
- AARA Research Center
-
Frisco, Texas, United States, 43235
- Ear Nose and Throat Associates of Texas
-
Plano, Texas, United States, 75093
- ENTTEX
-
-
Virginia
-
Norfolk, Virginia, United States, 23507
- EVMS Depart. Of Otolaryngology
-
-
Wisconsin
-
Greenfield, Wisconsin, United States, 53228
- Allergy, Asthma & Sinus Center, S.C.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men or women aged 18 years and older
Women must
- be practicing an effective method of birth control (eg,prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, double-barrier method [eg, condoms, diaphragm, or cervical cap with spermicidal foam, cream, or gel], or male partner sterilization) before entry and throughout the study, or
- be surgically sterile (have had a hysterectomy or bilateral oophorectomy, or tubal ligation at least 1 year before screening) or otherwise be incapable of pregnancy, or
- be postmenopausal (spontaneous amenorrhea for at least 1 year).
- Women of child-bearing potential must have a negative serum beta-human chorionic gonadotropin (B-hCG) or urine pregnancy test (depending on local regulations) at the screening visit
- Must have bilateral nasal polyposis with a grade of 1 to 3 in each of the nasal cavities as determined by the Lildholdt scale score measured by nasoendoscopy at both screening and baseline visits
- Must have at least moderate symptoms of nasal congestion/obstruction as reported by the subject for the 7 day period preceding the screening visit
- At the baseline visit (Day 1), must have a morning score of at least 2 (moderate) on nasal congestion/obstruction recorded on the subject diary for at least 5 of the last 7 days of the 7 to up to 14 day run-in period
- Must demonstrate an ability to correctly complete the daily diary during the run-in period to be eligible for randomization
- Subjects with comorbid asthma or COPD must be stable with no exacerbations (eg, no emergency room visits, hospitalizations, or oral or parenteral steroid use) within the 3 months before the screening visit. Inhaled corticosteroid use must be limited to stable doses of no more than 1,000 μg/day of beclomethasone (or equivalent) for at least 3 months before screening with plans to continue use throughout the study.
- Must be able to cease treatment with intranasal medications including, but not limited to, intranasal steroids, intranasal sodium cromolyn, nasal atropine, nasal ipratropium bromide, inhaled corticosteroids (except permitted doses listed above for comorbid asthma and COPD) at the screening visit
- Must be able to cease treatment with oral and nasal decongestants and antihistamines at the screening visit
- Must be able to use the OptiNose device correctly; all subjects will be required to demonstrate correct use of the placebo device at screening, Visit 1.
- Must be capable, in the opinion of the investigator, of providing informed consent to participate in the study. Subjects must sign an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.
Exclusion Criteria:
- Women who are pregnant or lactating
- Have complete or near-complete obstruction of the nasal cavities
- Inability to achieve bilateral nasal airflow for any reason including nasal septum deviation
- Inability to have each nasal cavity examined for any reason including nasal septum deviation
- Nasal septum perforation
- Has had more than 1 episode of epistaxis with frank bleeding in the month before the screening visit
- Have evidence of significant baseline mucosal injury, ulceration or erosion (eg, exposed cartilage, perforation) on baseline nasal examination/nasal endoscopy
- History of more than 5 sinonasal surgeries for either nasal polyps or nasal/sinus inflammation (lifetime)
- History of sinus or nasal surgery within 6 months before the screening visit
- History of any surgical procedure that prevents the ability to accurately grade polyps
- Have symptoms of seasonal allergic rhinitis at screening or baseline and/or, based on time of year, would anticipate onset of symptoms within 4 weeks of randomization
- Current, ongoing rhinitis medicamentosa (rebound rhinitis)
- Have significant oral structural abnormalities, eg, a cleft palate
- Diagnosis of cystic fibrosis
- History of Churg-Strauss syndrome or dyskinetic ciliary syndromes
- Purulent nasal infection, acute sinusitis, or upper respiratory tract infection within 2 weeks before the screening visit. Potential subjects presenting with any of these infections may be rescreened 4 weeks after symptom resolution Note: Subjects who are taking prophylactic antibiotics will be allowed to enter the study as long as they intend to continue the antibiotics for the duration of the study.
- Planned sinonasal surgery during the period of the study
- Allergy, hypersensitivity, or contraindication to corticosteroids or steroids
- Allergy or hypersensitivity to any excipients in study drug
- Exposure to any glucocorticoid treatment with potential for systemic effects (eg, oral, parenteral, intra-articular, or epidural steroids, high dose topical steroids) within 1 month before the screening visit; except as noted in inclusion criteria for subjects with comorbid asthma or COPD
- Have nasal candidiasis
- Have taken a potent CYP3A4 inhibitor within 14 days before the screening visit.
- History or current diagnosis of any form of glaucoma or ocular hypertension (ie, >21 mmHg)
- History of intraocular pressure elevation on any form of steroid therapy
- History or current diagnosis of the presence (in either eye) of a cataract
- Any serious or unstable concurrent disease, psychiatric disorder, or any significant condition that, in the opinion of the investigator could confound the results of the study or could interfere with the subject's participation or compliance in the study
- A recent (within 1 year of the screening visit) clinically significant history of drug or alcohol use, abuse, or dependence that, in the opinion of the investigator could interfere with the subject's participation or compliance in the study
- Positive urine drug screen at screening visit for drugs of abuse, with the exception of prescribed medications for legitimate medical conditions
- Have participated in an investigational drug clinical trial within 30 days of the screening visit
- Employees of the investigator or study center, with direct involvement in the proposed study or other studies under the direction of that investigator or study center, as well as family members of the employees or the investigator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: OPN-375 100 μg BID
Double-Blind Treatment Phase: OPN-375 100 μg BID x 16 weeks Open-Label Extension Phase: OPN-375 400 μg BID x 8 weeks |
Delivered via Optinose Exhalation Delivery System
Other Names:
|
Placebo Comparator: Placebo
Double-Blind Treatment Phase: Matching Placebo BID x 16 weeks Open-Label Extension Phase: OPN-375 400 μg BID x 8 weeks |
Delivered via Optinose Exhalation Delivery System
Other Names:
|
Active Comparator: OPN-375 200 μg BID
Double-Blind Treatment Phase: OPN-375 200 μg BID x 16 weeks Open-Label Extension Phase: OPN-375 400 μg BID x 8 weeks |
Delivered via Optinose Exhalation Delivery System
Other Names:
|
Active Comparator: OPN-375 400 μg BID
Double-Blind Treatment Phase: OPN-375 400 μg BID x 16 weeks Open-Label Extension Phase: OPN-375 400 μg BID x 8 weeks |
Delivered via Optinose Exhalation Delivery System
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in 7-day Average Instantaneous Morning Diary Congestion/Obstruction Symptoms
Time Frame: Baseline, Week 4 of the double-blind treatment phase
|
Subjects reported nasal symptoms using the electronic diary twice daily immediately before dosing. 0: None
The change from baseline in instantaneous morning diary symptom scores averaged over 7 days prior to the Week 4 Visit of the double-blind treatment phase |
Baseline, Week 4 of the double-blind treatment phase
|
Change in Total Polyp Grade
Time Frame: Baseline, Week 16 of the double-blind treatment phase
|
Polyp grading of each nasal cavity was determined by a nasal polyp grading scale score measured by nasoendoscopy. A summary of the changes from baseline to Week 16 in total polyp grade. 0: No polyps
Reduction in total polyp grade (sum of scores from both nasal cavities) at Week 16 of double-blind treatment phase; Included patients with nasal polyps at baseline |
Baseline, Week 16 of the double-blind treatment phase
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Congestion/Obstruction Scores (7-day Instantaneous Morning)
Time Frame: Baseline, Week 16 of the double-blind treatment phase
|
Subjects reported nasal symptoms using the electronic diary twice daily immediately before dosing. 0: None
The change from baseline in instantaneous morning diary symptom scores averaged over 7 days prior to the Week 16 Visit of the double-blind treatment phase |
Baseline, Week 16 of the double-blind treatment phase
|
Change in Rhinorrhea Score (7-day Instantaneous Morning)
Time Frame: Baseline, Week 16 of the double-blind treatment phase
|
Subjects reported nasal symptoms using the electronic diary twice daily immediately before dosing. 0: None
The change from baseline in instantaneous morning diary symptom scores averaged over 7 days prior to the Week 16 Visit of the double-blind treatment phase |
Baseline, Week 16 of the double-blind treatment phase
|
Facial Pain or Pressure Score (7-day Instantaneous Morning)
Time Frame: Baseline, Week 16 of the double-blind treatment phase
|
Subjects reported nasal symptoms using the electronic diary twice daily immediately before dosing. 0: None
The change from baseline in instantaneous morning diary symptom scores averaged over 7 days prior to the Week 16 Visit of the double-blind treatment phase |
Baseline, Week 16 of the double-blind treatment phase
|
Hyposmia Score (7-day Instantaneous Morning)
Time Frame: Baseline, Week 16 of the double-blind treatment phase
|
Subjects reported nasal symptoms using the electronic diary twice daily immediately before dosing. 0: None
The change from baseline in instantaneous morning diary symptom scores averaged over 7 days prior to the Week 16 Visit of the double-blind treatment phase |
Baseline, Week 16 of the double-blind treatment phase
|
Sinonasal Outcome Test 22 (SNOT-22) Total Score
Time Frame: Baseline, Week 16 of the double-blind treatment phase, Week 24 of the end of open-label treatment phase
|
SNOT-22 is a subject-completed questionnaire that consists of 22 questions. The questions on the SNOT-22 efficacy evaluation were used to calculate a total score. 22 questions are divided among 4 subscales: Rhinologic (7 questions), Ear/Facial Symptoms (4 questions), Sleep Function (3 questions), and Psychological Issues (6 questions). Each item was rated on the 5-point scale. The total score can range from 0-110, 0 being the best and 110 being the worst. 0: No problem
|
Baseline, Week 16 of the double-blind treatment phase, Week 24 of the end of open-label treatment phase
|
MOS Sleep-R Score
Time Frame: Baseline, Week 16 of the double-blind treatment phase
|
The MOS Sleep-R is a brief, self-administered, validated questionnaire designed to measure key aspects of sleep, such as disturbance, adequacy, somnolence, and quantity.
The 12-item version with a 4-week recall was used in this study.
The score range for the 12-item version is 0 to 100, lower scores indicating better sleep and higher scores indicating worse sleep.
The scale yields a Sleep Problem Index and scores on the following 6 subscales: Sleep Disturbance, Snoring, Shortness of Breath or Headache, Sleep Adequacy, Sleep Somnolence, and Sleep Quantity.
|
Baseline, Week 16 of the double-blind treatment phase
|
Rhinosinusitis Disability Index (RSDI) Total Score
Time Frame: Baseline, Week 16 of the double-blind treatment phase
|
The RSDI is a subject-completed instrument that evaluates the self-perceived impact of disease specific head and neck disorders.
The RSDI has 30 items in 3 domains: Physical (11 items), Functional (9 items), and Emotional (10 items).
The RSDI scale ranges from 0-120, 0 being better quality of life and less impact of CRS on daily function and 120 being worse quality of life and more impact of CRS on daily function.
|
Baseline, Week 16 of the double-blind treatment phase
|
SF-36v2 - Mental Component
Time Frame: Baseline, Week 16 of the double-blind treatment phase, Week 24 of the end of open-label treatment phase
|
The SF-36v2 is a multipurpose, scaled, 36-item, subject-completed validated questionnaire that measures 8 domains of health: limitations in physical activities, limitations in social activities, limitations in usual role activities, bodily pain, general mental health, limitations in usual role activities, vitality, and general health.
It yields scale scores for each of the 8 health domains, and 2 summary measures of physical and mental health.
Each scale range is from 0-100.
A lower score means more disability and a higher score means less disability.
|
Baseline, Week 16 of the double-blind treatment phase, Week 24 of the end of open-label treatment phase
|
SF-36v2 - Physical Component
Time Frame: Baseline, Week 16 of the double-blind treatment phase, Week 24 of the end of open-label treatment phase
|
The SF-36v2 is a multipurpose, scaled, 36-item, subject-completed validated questionnaire that measures 8 domains of health: limitations in physical activities, limitations in social activities, limitations in usual role activities, bodily pain, general mental health, limitations in usual role activities, vitality, and general health perceptions.
It yields scale scores for each of the 8 health domains, and 2 summary measures of physical and mental health.
Each scale range is from 0-100.
A lower score means more disability and a higher score means less disability.
|
Baseline, Week 16 of the double-blind treatment phase, Week 24 of the end of open-label treatment phase
|
Patient Global Impression of Change (PGIC) Score
Time Frame: Week 16 of the double-blind treatment phase, Week 24 of the end of open-label treatment phase
|
Subject responses to the question: "Since starting the study drug, how would you rate the change in your symptoms?"
Percentage includes patients who scored either "very much improved," "much improved," or "minimally improved."
|
Week 16 of the double-blind treatment phase, Week 24 of the end of open-label treatment phase
|
Peak Nasal Inspiratory Flow (PNIF)
Time Frame: Baseline, Week 16 of the double-blind treatment phase, Week 24 of the open-label treatment phase
|
The PNIF is an assessment of nasal passage obstruction and was measured using an In-Check portable nasal inspiratory flow meter.
To measure PNIF, a mask was placed over the nose during inspiration and inspiratory flow was recorded.
Each subject inhaled 3 times and each measurement was recorded.
The PNIF value used was the greatest of the 3 results at each time point.
|
Baseline, Week 16 of the double-blind treatment phase, Week 24 of the open-label treatment phase
|
Polyp Grade of 0 in at Least One Nostril
Time Frame: Baseline, Week 16 of the double-blind treatment phase, Week 24 of the end of open-label treatment phase
|
Polyp grading of each nasal cavity was determined by a nasal polyp grading scale score measured by nasoendoscopy. This outcome measured how many patients with a polyp grad of 0 in at least 1 nostril. 0: No polyps
|
Baseline, Week 16 of the double-blind treatment phase, Week 24 of the end of open-label treatment phase
|
Nasal Polyp Surgery Eligilbilty
Time Frame: Baseline, Week 16 of the double-blind treatment phase, Week 24 of the open-label extension phase
|
A subject was considered eligible for surgical intervention if the following conditions were met:
|
Baseline, Week 16 of the double-blind treatment phase, Week 24 of the open-label extension phase
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Ow RA, McGinnis JP 2nd, Sacks HJ, Mehle ME. The Effect of EDS-FLU on Objective and Patient-Reported Subjective Outcomes for Patients with Chronic Rhinosinusitis with Nasal Polyps. Ear Nose Throat J. 2022 Apr 18:1455613221088698. doi: 10.1177/01455613221088698. Online ahead of print.
- Skoner DP, Meltzer EO, Skoner J, Sacks HJ, Lumry WR. Evaluation of the ocular safety associated with the exhalation delivery system with fluticasone. Allergy Asthma Proc. 2022 Jan 9;43(1):70-77. doi: 10.2500/aap.2022.43.210096. Epub 2021 Nov 9.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Respiratory Tract Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Pharyngeal Neoplasms
- Otorhinolaryngologic Neoplasms
- Head and Neck Neoplasms
- Nasopharyngeal Diseases
- Pharyngeal Diseases
- Stomatognathic Diseases
- Otorhinolaryngologic Diseases
- Colonic Diseases
- Intestinal Diseases
- Pathological Conditions, Anatomical
- Intestinal Neoplasms
- Rectal Diseases
- Nose Diseases
- Polyps
- Nasopharyngeal Neoplasms
- Colorectal Neoplasms
- Nasal Polyps
- Physiological Effects of Drugs
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Dermatologic Agents
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Anti-Allergic Agents
- Fluticasone
- Xhance
Other Study ID Numbers
- OPN-FLU-NP-3101
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bilateral Nasal Polyposis
-
Optinose US Inc.CompletedBilateral Nasal PolyposisUnited States
-
Optinose US Inc.RecruitingBilateral Nasal PolyposisUnited States
-
Idorsia Pharmaceuticals Ltd.CompletedBilateral Nasal PolyposisGermany, Belgium
-
Fondation Ophtalmologique Adolphe de RothschildCompletedChronic Rhinosinusitis With Nasal Polyposis (CRSwNP)
-
Optinose US Inc.CompletedNasal PolyposisUnited States
-
Central Hospital, Nancy, FranceUnknown
-
Université de SherbrookeTerminatedChronic Rhinosinusitis (Diagnosis), Nasal PolyposisCanada
-
Keymed Biosciences Co.LtdNot yet recruitingChronic Rhinosinusitis With Nasal Polyposis
-
Regeneron PharmaceuticalsSanofiRecruitingChronic Rhinosinusitis With Nasal PolyposisUnited States, Italy, Canada, Japan, Germany, Netherlands
-
Yuzuncu Yıl UniversityCompleted
Clinical Trials on Fluticasone Propionate
-
University of FloridaFood and Drug Administration (FDA)Completed
-
GlaxoSmithKlineCompleted
-
Teva Pharmaceuticals USATerminatedSeasonal Allergic RhinitisUnited States
-
PfizerCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedAsthmaUnited States, Argentina, Philippines, Canada, Brazil
-
Padagis LLCCompleted
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom
-
Boehringer IngelheimCompletedAsthmaUnited States, Australia, Canada, Colombia, Korea, Republic of, Mexico, New Zealand, Peru, Philippines, Taiwan